NIVFW
NewGenIvf Group Limited
NASDAQ · Healthcare · Medical - Care Facilities · VG
$0.02
+5.26%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.5M | 4.7M | 5.4M | 5.1M | 5.9M |
| Cost of Revenue | 3.6M | 3.8M | 3.6M | 3.5M | 4.4M |
| Gross Profit | 1.8M | 955.8K | 1.8M | 1.7M | 1.5M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 10.2M | 11.7M | 3.0M | 1.6M | 1.1M |
| General & Admin Expense | 9.2M | 10.5M | 2.8M | 1.6M | 1.1M |
| Selling & Marketing Expense | 1.0M | 1.2M | 206.3K | 18.0K | 36.2K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 10.2M | 11.7M | 3.0M | 1.6M | 1.1M |
| Cost and Expenses | 13.8M | 15.5M | 6.6M | 5.1M | 5.5M |
| Operating Income (EBIT) | (8.4M) | (10.7M) | (1.2M) | 42.2K | 398.7K |
| Non-Operating | |||||
| Interest Income | 5.2K | 2.3K | 7.0K | 518.00 | 21.00 |
| Interest Expense | 1.2M | 616.4K | 778.7K | 46.2K | 77.8K |
| Net Interest Income | (1.2M) | (614.2K) | (772.0K) | (45.7K) | (77.7K) |
| Other Non-Op Income/Expense | 16.8M | 20.5M | 199.7K | 66.2K | (54.7K) |
| Non-Operating Income (excl Interest) | (18.0M) | (21.1M) | (978.0K) | (112.0K) | (23.0K) |
| EBT (Pre-Tax Income) | 8.5M | 9.7M | (961.0K) | 108.4K | 344.0K |
| Income Tax Expense | (487.0K) | — | (487.0K) | — | 208.1K |
| Bottom Line | |||||
| Net Income | 9.0M | 9.9M | (525.0K) | 130.2K | 458.7K |
| Earnings from Cont. Ops | 8.9M | 9.7M | (474.0K) | 108.4K | 135.8K |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 9.0M | 9.9M | (525.0K) | 130.2K | 458.7K |
| Per Share | |||||
| Basic EPS | $86.91 | $151.20 | ($200.76) | $111.92 | $562.64 |
| Diluted EPS | $86.91 | $151.20 | ($200.76) | $111.92 | $562.64 |
| Revenue Per Share | $83.44 | $72.31 | $83.13 | $176.31 | $204.04 |
| Shares | |||||
| Basic Shares Outstanding | 65359 | 65359 | 65359 | 29132 | 29132 |
| Diluted Shares Outstanding | 65359 | 65359 | 65359 | 29132 | 29132 |
| Profitability Metrics | |||||
| EBITDA | 9.8M | 10.8M | 24.3K | 384.3K | 725.7K |
| D&A | 189.2K | 499.5K | 206.3K | 229.7K | 303.9K |
| EBIT | 9.6M | 10.3M | (182.0K) | 154.6K | 421.7K |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025